Novartis to expand gene therapy pipeline with acquisition of AveXis for $8.7 billion – Chemical & Engineering News
Zacks.com |
Novartis to expand gene therapy pipeline with acquisition of AveXis for $8.7 billion
Chemical & Engineering News Novartis plans to acquire the neurological gene therapy firm AveXis for $8.7 billion. The purchase will bolster the Swiss giant’s standing as a big pharma leader in the emerging gene therapy field. AveXis’s leading drug candidate is its gene therapy to … Gene Therapy in Limelight on Novartis Deal: 3 Stocks in FocusZacks.com GSK Signs Strategic Agreement To Transfer Rare Disease Gene …Clinical Leader Orchard Therapeutics to buy GSK’s rare disease gene therapy portfolioPharmaceutical Business Review Nasdaq –Hospital Healthcare Europe –Pharmaceuticals News all 14 news articles » |
FierceBiotech |
Pfizer puts Bamboo’s muscular dystrophy gene therapy to the test
FierceBiotech At least two other trials of DMD gene therapies are also ongoing in the U.S., both involving candidates developed at Nationwide Children’s Hospital (NCH) and partnered by Sarepta. One of the two phase 1/2 trials is based on delivery of a … |
Xconomy |
Bio Roundup: Lung Cancer Showdown, Gene Therapy Deals, IPO Busts
Xconomy Elsewhere this week, Novartis bet heavily on gene therapy while GlaxoSmithKline asked out, the Theranos saga rolled on, and a few biotechs to go public since 2015 crashed and burned. Let’s round it all up. CANCER HEADLINES. —This year’s American … |
Xconomy |
Bio Roundup: Lung Cancer Showdown, Gene Therapy Deals, IPO Busts
Xconomy Elsewhere this week, Novartis bet heavily on gene therapy while GlaxoSmithKline asked out, the Theranos saga rolled on, and a few biotechs to go public since 2015 crashed and burned. Let’s round it all up. CANCER HEADLINES. —This year’s American … |